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Abstract Descriptive epidemiology of the myelodysplastic
syndromes (MDS) is always interesting and may reveal time-
dependent and geographical variations, as well as occupatio-
nal exposure. Epidemiological data in Greece are not available
by now.We have collected and analyzedmedical records of all
patients with a documented diagnosis of MDS, performed by
an expert hematologist and/or hematopathologist, in the geo-
graphical area of Western Greece, during the 20-year period,
defined between 1990 and 2009. We have then calculated and
described demographic and clinical features of the diagnosed
MDS patient population, and assessed the incidence and pre-
valence rates of MDS in Western Greece, during the above-
mentioned period. A total of 855 patients with newly diag-
nosed MDS have been identified. Refractory anemia was the
most common subtype in both FAB and WHO classification
systems and in both genders. Del-5q and RARS were more
commonly encountered among females, and the dysplastic
subtype of chronic myelomonocytic leukemia among
males. Trisomy 8 was the most common single cytogene-
tic abnormality. The crude mean annual incidence rate of
MDS was 6.0 per 100,000 inhabitants aged ≥15 years old
(all subtypes according to FAB), and it was 4.8 per
100,000 when CMML and RAEB-T were excluded. Crude
incidence rate was higher in rural than in urban areas, but
this finding was not confirmed after age standardization.
Age-standardized mean annual incidence rate in men was
7.9/100,000 and in women 3.4/100,000. A continuously
increasing incidence rate of MDS has been observed
throughout the study period.
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Introduction
Myelodysplastic syndromes (MDS) are acquired clonal he-
matopoietic stem cell disorders, characterized by ineffective
hematopoiesis, peripheral blood cytopenias, and increased
risk of leukemic transformation. The incidence of MDS is
not worldwide known, and this is attributed to many reasons.
First, there are frequent diagnostic inconsistencies, leading to
erroneous classification of many cases with borderline fea-
tures, as other diseases, such as aplastic anemia, anemia of
inflammation, myeloproliferative neoplasms, and acute mye-
logenous leukemia. Second, there is occasional difficulty in
making the correct diagnosis, especially when morphologic
features are subtle or inadequate [1]. Indeed, dysplastic fea-
tures in the peripheral blood or bone marrow (BM) may
accompany a large number of chronic diseases or conditions,
particularly in the elderly, of inflammatory, endocrine, auto-
immune, or neoplastic etiology, or they may be a consequence
of advanced age alone [2]. Third, the diagnosis of MDS in
very elderly patients may not be confirmed, due to reluctance
of patients and/or physicians to perform a BM examination
[3]. Another reason for lacking data is that systemic registra-
tion of MDS has only recently been started, even in countries
with well-organized and active cancer registries.
The incidence of MDS varies significantly by geographical
area, and this has been attributed to genetic, occupational,
lifestyle, and environmental factors, not fully elucidated as
yet [4]. According to published epidemiological studies, the
mean annual incidence varies between 1/100,000 inhabitants
in Japan [5] and 12.6 in the area of Bournemouth, UK (1981–
1990) [6]. Data on the incidence and prevalence of MDS in
Greece have not been published by now.
The objective of the present study was to describe demo-
graphic and clinical features of patients with MDS in West-
ern Greece, during the previous two decades, and to
estimate incidence and prevalence rates in a demographical-
ly well-defined population of the same area.
Materials and methods
Western Greece is defined geographically as the area southern
of Epirus, western of Fokida and Eurytania in the Greek
mainland, as well as western of Korinthia and Arcadia, and
northern of Messinia in Peloponnese (Fig. 1). In this area,
consisting of three prefectures, Achaia, Ilia, and Etolia and
Akarnania, there is one major, fully occupied hospital-referral
center, the University Hospital of Patras, a second major,
referral hospital, “St Andrew” Hospital, and two smaller hos-
pitals with a Department of Hematology. The University
Hospital possesses an expert Hematopathology laboratory
and accepts patients from the whole area, referred by physi-
cians of smaller hospitals and private practice. Patients are
also referred from neighbor territories, such as the Ionian
islands (Kefallinia, Zakynthos, Ithaca, and Lefkas), and the
closest parts of Korinthia, Fokida, and Messinia. In our area
patients with hematological dyscrasias are not treated or
followed by other specialists or private practice centers.
Medical records and electronic databases of the four
above-mentioned hospitals were reviewed, and all patients
with MDS diagnosed between 1.1.1990 and 31.12.2009
were registered. Only patients with a documented diagnosis
of MDS, confirmed by BM examination (aspiration and/or
biopsy), were included in the analysis. The study has been
approved by the Ethical and Scientific Council of the par-
ticipating hospitals.
Demographic data, as well as disease information (FAB
and WHO classification, cytogenetics, laboratory findings at
diagnosis, IPSS, transfusion dependency, WPSS, and leuke-
mic evolution) were collected and analyzed for all patients
(aged ≥15 years) diagnosed during the study period. Pedi-
atric MDS cases have not been included in this analysis.
Patients residing in the three prefectures of Western Greece
were then selected for the estimation of epidemiological indices.
The adult population of the area was considered stable during
the study period and consisted of 603,543 inhabitants. Demo-
graphic data were based on the 2001 national census, provided
by the General Secretariat of the Hellenic Statistical Authority.
Statistical analysis
Statistical analysis was performed by using the Statistical
Software IBM SPSS Statistics 20. t test (Student’s test) was
used for the comparison of means, Chi square (χ2) test for
the comparison of percentages between subgroups, and
analysis of variance was performed to compare means be-
tween several subgroups. The comparison of age-
standardized incidence rates was performed using the com-
parative morbidity figure (CMF). The standard error and
95 % confidence intervals (95 % CI) of CMF were calcu-
lated according to the method of Breslow and Day [7, 8].
Results
Demographic features
Totally, 855 patients were diagnosed with an MDS between
1.1.1990 and 31.12.2009 in Western Greece. Among them,
Fig. 1 Map of Greece, where the area of Western Greece (prefectures
of Achaia, Ilia, and Etolia/Akarnania) is depicted in yellow (inserted
picture). In the enlarged map of Western Greece, the red rectangle
indicates the urban area of Patras, regional capital of Western Greece.
The yellow arrow depicts the position of the Rion-Antirion bridge,
which connects Peloponnese with continental Greece
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606 (71 %) were males and 249 (29 %) females (M/F ratio
2.43:1). Mean age at diagnosis was 73.1±18.9 years (medi-
an 74) and it was not significantly different between men
and women, in each MDS subtype, and overall. However,
age at diagnosis was significantly different by FAB subtype,
and patients with RAEB-T were younger (p=0.008).
Among the 855 patients, 721 (84.3 %) were living in
Western Greece [Achaia (N= 371), Ilia (N= 175),
Etolia/Akarnania (N=175)], and 134 (15.7 %) in neighbor
prefectures, [Kefallinia and Zakynthos (N=41), Korinthia
(N=28), Fokida (N=15), Messinia (N=14), and other (N=
36)]. Four hundred and eighty-three patients (56.7 %) were
living in rural or semi-urban areas, whereas 341 (39.9 %)
resided in urban areas. For 29 patients (0.3 %) the area of
residence was unknown.
Occupation was known in 640 patients (75 %) and almost
half of them were farmers [N=279 (44 %)]. Other frequently
encountered occupations were housekeeping [N=84 (13 %)],
merchantry [N=37 (6%)], public administration [N=21 (3%)],
industrial worker [N=21 (3 %)], policeman [N=16 (2.5 %)],
office employee [N=13 (2 %), and teacher [N=12 (2 %)].
Clinical and laboratory features
Presenting symptoms were known in 597 patients (70 %)
and the most common were fatigue in 330 (55 %), fever or
infection in 88 (15 %), and bleeding in 50 (8 %). In 126
patients (21 %) diagnosis was suspected by routine blood
tests, while they were completely asymptomatic.
Totally, 833 patients (97.4 %) had primary, and 22
(2.6 %) secondary or therapy-related MDS, following pre-
vious exposure to chemo-/radiotherapy. Moreover, 67 cases
(7.8 %) were fibrotic MDS, based on their substantial in-
crease of BM reticulin fibers, and additional 38 (4.4 %) had
hypoplastic-type MDS (BM cellularity ≤30 %).
Baseline hematological parameters were available in 776
patients (90.8 %) and 63.5 % had moderate to severe anemia
(hemoglobin <10 g/dl), 33.4 % had neutropenia (ANC
<1.5x109/μl), and 40.9 % had thrombocytopenia (PLT
<100×109/μl). Moreover, 35.4 % of the patients had various
bicytopenias and 12.1 % were pancytopenic. The presence
and the various combinations of cytopenias at diagnosis are
summarized in Table 1.
FAB and WHO classification
The distribution according to FAB classification was as
follows: refractory anemia (RA) 313 patients, RA with
ringed sideroblasts (RARS) 82, RA with excess of blasts
(RAEB) 287, RAEB in transformation (RAEB-T) 34,
chronic myelomonocytic leukemia (CMML) 123, and un-
classified MDS 16. RARS was more frequent in women, yet
this difference was not statistically significant.
According to the WHO classification 176 patients had RA,
16 Del(5q) syndrome, 53 RARS, 122 refractory cytopenia with
multilineage dysplasia (RCMD), 24 RCMD with ringed
sideroblasts (RCMD-RS), 162 RAEB-1, 123 RAEB-2, 52
CMML-dysplastic (CMML-D), 71 CMML-proliferative
(CMML-P), 16 other hybridmyelodysplastic/myeloproliferative
disorders (MDS/MPD, including four with RARS-T), six un-
classified MDS, and 34 AML. Del-5q syndrome (p=0.006) and
RARS (p=0.039) were more frequent in women, whereas
CMML-D was more common in men (p=0.002, Table 2).
Cytogenetic abnormalities
Cytogenetic analysis was performed in 611 patients (71 %),
but in 20 (3.3 %) it could not be assessed due to absence of
metaphases. Therefore, karyotype was available in 591 pa-
tients and it was normal in 364 (61.6 %) and abnormal in 227
(38.4 %). The most commonly detected cytogenetic abnor-
malities were: trisomy 8 (8.3 %), loss of Υ (5.8 %), and
multiple (≥3) or complex chromosomal abnormalities
(7.6 %). Del(5q) was found in 2.7 % and chromosome 7
abnormalities in 3 % of the patients. Loss of chromosome Y
was considered a clonal abnormality, when >50 % of a
minimum of 20 metaphases analyzed were demonstrating
−Y. The kind of the detected chromosomal abnormalities
among the total population tested, as well as among patients
with a detected abnormal karyotype, is demonstrated in
Table 3.
Table 1 Cytopenias and hematological parameters at diagnosis in 776
patients with MDS
Cytopenia at diagnosis N (%)
Anemia (Hb <10 g/dl) 493 (63.5)
Neutropenia (ANC <1,500/mm3) 259 (33.4)
Thrombocytopenia (PLT<100,000 mm3) 317 (40.9)
Anemia and neutropenia 161 (20.7)
Anemia and thrombocytopenia 207 (26.7)
Neutropenia and thrombocytopenia 141 (18.2)
Pancytopenia 95 (12.2)
Laboratory values at presentation Mean P
Hemoglobin—men (N=549) 9.6 g/dl <0.0001
Hemoglobin—women (N=227) 9.1 g/dl
Hemoglobin—all patients 9.5 g/dl
White blood cells—men 7.88×109/l 0.096
White blood cells—women 6.66×109/l
White blood cells—all patients 7.52×109/l
Abs. neutrophil count—men 4.10×109/l 0.191
Abs. neutrophil count—women 3.55×109/l
Abs. neutrophil count—all patients 3.94×109/l
Platelet count—men 154×109/l 0.156
Platelet count—women 169×109/l
Platelet count—all patients 158×109/l
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Prognostic classification according to IPSS and WPSS
IPSS could be assessed in 591 patients (69 %) and it was
low in 236, intermediate-1 in 193, intermediate-2 in 105,
and high in 57 patients. No difference in the distribution of
men and women was found [low—(i.e., low/Int-1) vs. high-
risk (i.e., Int-2/high)], p=0.269].
WPSS could be assessed in 470 patients. In 207 patients
cytogenetic results were unavailable, and therefore the
WPSS could not be calculated, whereas in additional 178,
WPSS was not applicable, either for a disease entity not
assigned to the WHO classification (177), or for missing
transfusion requirements (1). Patient distribution according
to IPSS and WPSS is shown in Table 2.
Leukemic evolution
After a mean duration of dysplastic phase of 26 months (range
0.1–204 months), disease progressed to a more aggressive
MDS or AML in 275 patients (32 %), whereas no progression
Table 2 Distribution according
to FAB and WHO classification,
IPSS, and WPSS
No significant difference be-
tween men and women,
according to FAB and to IPSS
was observed. Del-5q syndrome
and RARS were more frequent
in women (4 % vs. 1 %, p=
0.006, and 8.8 % vs. 5.1 %, p=
0.039, respectively), whereas
CMML-D was more frequent in
men (7.8 % vs. 2 %, p=0.002).
WPSS very low subgroup was
more frequent in women (36.2 %
vs. 26.8 %, p=0.047), whereas
intermediate subgroup was more
frequent in men (19.2 % vs.
7.1 %, p=0.001).
Group Νo. Percent Men Percent Women Percent p value
FAB classification
RA 313 36.6 214 35.3 99 39.8 0.223
RARS 82 9.6 51 8.4 31 12.4 0.073
RAEB 287 33.6 212 35.0 75 30.1 0.170
RAEB-T 34 4.0 23 3.8 11 4.4 0.277
CMML 123 14.5 93 15.3 30 12.0 0.213
Unclassified 16 1.9 13 2.1 3 1.2 0.447
WHO-2001 classification
RA 176 20.66 121 20.0 55 22.1 0.491
Del (5q) 16 1.9 6 1.0 10 4.0 0.006
RCMD 122 14.3 87 14.4 35 14.1 0.900
RARS 53 6.2 31 5.1 22 8.8 0.039
RCMD-RS 24 2.8 16 2.6 8 3.2 0.649
RAEB-1 162 18.9 121 20.0 41 16.5 0.234
RAEB-2 123 14.4 91 15.0 32 12.9 0.415
AML 34 4.0 24 4.0 10 4.0 0.277
CMML-D 52 6.1 47 7.8 5 2.0 0.002
CMML-P 71 8.3 46 7.6 25 10.0 0.241
MDS/MPD (incl. RARS-T) 16 1.9 12 2.0 4 1.6 0.243
Unclassified/unknown 6 0.5 4 0.7 2 0.8 0.741
Total 855 100 606 100 249 100 –
IPSS risk group categorization
Low 236 39.9 172 39.2 64 42.1 0.557
Intermediate-1 193 32.6 152 34.6 41 27.0 0.128
Intermediate-2 105 17.8 76 17.3 29 19.1 0.622
High 57 9.6 39 8.9 18 11.8 0.293
Subtotal 591 100 439 100 152 100.0 –
Unknown IPSS 264 – 167 – 97 – n.s.
WPSS risk group categorization
Very low 138 29.4 92 26.8 46 36.2 0.047
Low 87 18.5 61 17.8 26 20.5 0.504
Intermediate 75 16.0 66 19.2 9 7.1 0.001
High 127 27.0 94 27.4 33 26.0 0.761
Very high 43 9.1 30 8.8 13 10.2 0.620
Subtotal 470 100 343 100 127 100.0 –
WPSS unknown 207 – 132 – 75 – n.s.
WPSS not applicable 178 – 131 – 47 – n.s.
Total 855 – 606 – 249 – –
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was observed in 503 (59 %). In 77 patients (9 %), progression
status was unknown. These patients were equally distributed
by gender (p=0.494) and by residence area (p=0.287), there-
fore the unknown cases could be excluded, and the rate of
disease evolution was again similar between the two genders
(p=0.174) or by residence area (p=0.988).
Disease progression paralleled to the IPSS and WPSS
risk group categorization (Table 5) and was lower in patients
<70 years (p<0.0001). Moreover, patients with RA and
RARS had lower progression rate than those with RCMD
and RCMD/RS (p<0.0001) and patients with RAEB-1 had
also lower progression rate, than those with RAEB-2 (p=
0.004). Disease progression was not significantly different
between CMML-D and CMML-P (p=0.405). The rates of
disease progression are presented in Table 4.
Incidence and prevalence rates
Incidence and prevalence rates were estimated for the pop-
ulation of Achaia, Ilia, and Etolia and Akarnania separately,
and for the whole adult population of Western Greece
(603,543 inhabitants). During the 20-year study period
(1990–2009) totally, 721 MDS patients were identified and
registered. Among them, 386 (53.5 %) were residents of
rural, and 315 (43.7 %) of urban areas, whereas for 20
patients (2.8 %) the residential area was unknown.
On 31.12.2009, 147 patients with MDS were alive, cor-
responding to a point prevalence of 24 cases per 100,000
inhabitants (0.024 %). The crude mean annual incidence of
MDS in the adult population of Western Greece during the
period 1990–2009 was 6.0 (95 % CI 5.6–6.4), while the age-
standardized incidence rate was 5.7 (95 % CI 5.3–6.1).
However, when CMML and RAEB-T were excluded (not
considered MDS according to WHO classification), the
crude mean annual incidence rate was estimated 4.8 (95 %
CI 4.8–5.2) per 100,000 (Table 5).
The age-specific mean annual incidence rate of MDS in-
creased with age, starting from 0.1/100,000 in the age group
15–39 years, 0.6 (40–49 years), 2.1 (50–59 years), 10 (60–
69 years), 28.4 (70–79 years), and 34.7 in the age
group >80 years (Table 6). There was a significant variation
in the crude incidence rates among the different areas, which
ranged from 2.8/100,000 inhabitants in the urban areas of
Etolia and Akarnania to 8.8/100,000 inhabitants in the rural
areas of Achaia. Moreover, there was an increased incidence of
MDS in Achaia in comparison to other prefectures (Table 7).
Given that the rural population is more senile than the
urban, and that the incidence of MDS increases with age, we
consequently performed a direct standardization method, to
compare the incidence between rural and urban areas, by using
as a standard population the whole adult population of Greece
in 2001. Age-standardized incidence of MDS in rural areas
was 5.9 (95 % CI 5.1–6.7) whereas, in urban areas was 5.2
(95 % CI 4.7–5.7). The CMF (ratio of incidence in rural/urban
areas) was 1.13 (95 % CI 0.96–1.33). Therefore, we did not
find a statistically significant difference in the incidence of
MDS between rural and urban areas after age standardization.
Crude incidence, as opposed to age-standardized incidence of
MDS in rural and in urban areas, is depicted in Fig. 2. We also
calculated age-standardized incidence rates of MDS for each
prefecture, and the difference (incidence in Achaia, compared
to that of the other prefectures) was even more remarkable.
Age-standardized incidence of MDS in men was 7.9 (95 % CI
7.1–8.7) and in women 3.4 (95 % CI 2.9–3.9). The CMF (ratio
of incidence in men/women) was 2.32 (95 % CI 1.96–2.75).
Sex-standardized incidence ofMDSwas 5.9 (95%CI 5.5–6.3)
per 100,000 inhabitants (Table 7).
We finally estimated the temporal trends in the incidence in
the same population throughout the study period, by dividing
it in 5-year intervals. The number of new MDS cases gradu-
ally increased from 130 during the quinquennium 1990–1994,
to 171 during 1995–1999, 190 during 2000–2004, and
Table 3 Cytogenetics in 591
patients with MDS
Italic figures demonstrate per-
centages among patients with an
abnormal karyotype
Patient population: All patients CMML and RAEBT excluded
Karyotype N % N %
Normal 364 61.6 (−) 294 60.7 (−)
Trisomy 8 49 8.3 (21.6) 35 7.2 (18.4)
Loss of Y 34 5.8 (15.0) 28 5.8 (14.7)
Del(5q) 16 2.7 (7.0) 16 3.3 (8.4)
Del(20q) 13 2.2 (5.7) 12 2.5 (6.3)
Chromosome 7 aberrations 18 3.0 (7.9) 17 3.5 (8.9)
Trisomy 21 6 1.0 (2.6) 3 0.6 (1.6)
Other single aberrations 19 3.2 (8.4) 19 3.9 (10.0)
Del(5q) plus add. abnormalities 7 1.2 (3.1) 7 1.4 (3.7)
Double abnormalities 20 3.4 (8.8) 17 3.5 (8.9)
Multiple/complex aberrations 45 7.6 (19.8) 36 7.4 (18.9)
Total 591 100.0 (100.0) 484 100.0 (100.0)
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eventually 230 during 2005–2009. The crude mean annual
incidence rate increased from 4.3 (95 % CI 3.6–5.0) per
100,000 inhabitants in the first period (1990–1994), to 5.7
(95 % CI 4.9–6.6) during 1995–1999, 6.3 (95 % CI 5.4–7.2)
during 2000–2004, and finally 7.6 (95 % CI 6.6–8.6) in the
last period (2005–2009). Thus, a statistically significant in-
crease of the overall incidence rate of MDS was observed
throughout the study period. To elucidate which MDS sub-
types mainly increased or whether all MDS subtypes propor-
tionally increased, we calculated the crude mean annual
incidence rates among pat ients with lower-r i sk
MD S ( FA B / R A - R A R S ) , h i g h e r - r i s k MD S
(RAEB/RAEBT/unclassified) and CMML separately. We
found that the observed increase in the annual incidence of
MDS in our area was almost entirely attributed to the lower-
riskMDS, whose incidence rose from 1.4/100,000 inhabitants
in the first period (1990–1994) to 4.4/100,000 in the last
quinquennium 2005–2009, demonstrating 214 % increase.
The incidence of higher-risk MDS and of CMML was prac-
tically unchanged throughout the 20-year period. The tempo-
ral trend of mean annual incidence rate of the whole MDS
population and of the higher- and lower-risk cases, as well as
that of CMML, through 1990–2009, is depicted in Fig. 3.
Discussion
Epidemiological studies on MDS are rare worldwide, but
particularly in Greece there are no data about the epidemi-
ology of these diseases. This is the first study which at-
tempts to describe demographic and clinical features of
patients with MDS, and to estimate incidence and preva-
lence rates in a well-defined geographical area of Greece.
A clear predominance of MDS in men has already been
reported. In two studies male to female ratio was estimated
1.9 [9], and 1.62 [10], but in our study it was even higher
(2.43). In our patient population the mean age at diagnosis
was not significantly different between men and women,
either overall or by subtype. In addition, there was a remark-
ably high representation of farmers. According to
Table 5 Comparison between evolution rates to AML by WHO subtype and by age
WHO subtype Total N Evolved (N) Percent Not evolved (N) Percent Unknown (N) Percent p value
RA/RARS 229 18 7.9 189 82.5 22 9.6 <0.0001
RCMD/RCMD-RS 162 41 25.3 106 65.4 15 9.2
RAEB-1 162 70 43.2 80 49.4 12 7.4 0.004
RAEB-2 123 65 52.8 41 33.3 17 13.8
CMML-D 52 19 36.5 31 59.6 2 3.8 0.405
CMML-P 71 29 40.8 35 49.3 7 9.6
Other subtypes 56 33 58.9 21 37.5 2 3.6 –
Age <70 years 241 105 43.6 123 51.0 13 5.4 <0.0001
Age ≥70 years 614 170 27.7 380 61.9 64 10.4
Table 4 Disease progression and evolution by MDS subtype
according to FAB and WHO classification, and by IPSS and WPSS
prognostic category
FAB classification Patients evolved Percent
RA 39/282 13.8
RARS 20/76 26.3
RAEB 136/257 52.9
RAEB-T 27/33 81.8
CMML 48/114 42.1
Unclassified 5/16 31.3
Total 275/778 35.3
Unknown 77
WHO classification
RA 13/158 8.2
Del (5q) 3/16 18.8
RCMD 23/110 20.9
RARS 5/49 10.2
RCMD-RS 15/22 68.2
RAEB-1 70/150 46.7
RAEB-2 65/106 61.3
CMML-D 19/50 38.0
CMML-P 29/64 45.3
MDS/MPD 8/16 50.0
Unclassified 1/6 16.7
IPSS (N=575)
Low 38/228 16.7
Int-1 76/189 40.2
Int-2 65/103 63.1
High 33/55 60.0
WPSS (Ν=444)
Very low 11/131 8.4
Low 18/81 22.2
Intermediate 33/77 42.9
High 69/114 60.5
Very high 18/41 43.9
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occupational data for the Hellenic population of Western
Greece during 2007–2009 (provided by the Hellenic Statis-
tical Authority), persons occupied with agricultural activi-
ties constituted 21 %, i.e., smaller than half of what we
found. Nevertheless, a safe comparison cannot be made,
because this percentage refers to persons of productive
age, whereas our patients were mostly elderly and declared
being farmers even after their retirement. This difference
may also depict an under-representation of occupations as-
sociated with higher socioeconomic status, since some of
these patients might have been treated in private centers of
Athens. This possibility however may be valid only for a
small minority of our patients. Alternatively, it could sug-
gest a true association between MDS and agricultural activ-
ity, but the investigation of this hypothesis exceeds the
limits of descriptive epidemiology.
We found that only 2.6 % of the patients had secondary
(therapy-related) MDS. This percentage is lower than what has
been previously reported (5.3–12.5 %) [9, 11–13], although in a
Spanish study no secondary MDS cases were identified [14].
The distribution according to FAB and WHO classification is
consistent with the results of previous studies. All MDS sub-
types, excluding Del-5q and RARS, were more frequent in men
[15]. RARS was more frequent in women, in both classification
systems, yet this difference was statistically significant only for
theWHO classification. Conversely, CMML-Dwas significant-
ly more frequent in men, as has been previously reported [16].
In our registry, karyotype is missing mostly in patients
diagnosed in the early 1990s, and, generally, the later the
diagnosis was made, the more cytogenetic studies are avail-
able, given the increased sensitization of experts about MDS.
Loss of chromosome Y was highly represented, but
Table 6 Age-specific incidence rates of MDS in Western Greece, 1990–2009, by gender and by residence in a rural or urban area
Men and women Men Women Rural areas Urban areas
Age group (years) N Rate N Rate N Rate N Rate N Rate
15–39 4 0.1 2 0.1 2 0.1 1 0.1 3 0.1
40–49 11 0.6 9 0.9 2 0.2 7 1.0 4 0.3
50–59 33 2.1 22 2.8 11 1.4 16 2.5 17 1.9
60–69 164 10.0 106 13.7 58 6.3 79 9.8 83 9.9
70–79 342 28.4 251 46.0 91 13.8 192 30.4 140 24.6
≥80 167 34.7 116 56.2 51 18.5 91 33.3 68 32.7
Total (crude) 721 6.0 506 8.3 215 3.6 386 7.7 315 4.5
Total crude (CMML and RAEB-T excluded) 585 4.8 405 6.7 180 3.0 309 6.1 260 3.7
Table 7 Crude and age-standardized incidence rates of MDS in the population of people aged 15 years and older in Western Greece during the
period 1990–2009 by prefecture, by rural, or urban area and by gender, comparative morbidity figures (CMF) and 95 % confidence intervals
Subgroup Crude (95 % CI) Age-standardized (95 % CI)
Prefecture
Achaia Rural areas 8.8 (7.3–10.3) 7.2 (5.9–8.5)
Urban areas 5.6 (4.8–6.4) 6.8 (6.0–7.6)
Overall 6.9 (6.2–7.6) 7.3 (6.6–8.0)
Ilia Rural areas 7.2 (5.9–8.5) 5.1 (4.1–6.1)
Urban areas 3.7 (2.7–4.7) 4.1 (3.1–5.1)
Overall 5.7 (4.9–6.5) 5.0 (4.2–5.8)
Etolia and Akarnania Rural areas 7.0 (5.8–8.3) 5.2 (4.2–6.2)
Urban areas 2.8 (2.0–3.6) 3.0 (2.2–3.8)
Overall 4.8 (4.1–5.5) 4.3 (3.6–5.0)
Comparison between subgroups CMF (95 % CI)
All prefectures Rural areas 7.7 (6.9–8.5) 5.9 (5.1–6.7) 1.13 (0.96–1.33)
Urban areas 4.5 (4.0–5.0) 5.2 (4.7–5.7)
Gender Men 8.3 (7.6–9.0) 7.9 (7.1–8.7) 2.32 (1.96–2.75)
Women 3.6 (3.1–4.1) 3.4 (2.9–3.9)
All subgroups Total 6.0 (5.6–6.4) 5.7 (5.3–6.1)
Sex-standardized incidence rate (95 % CI) 5.9 (5.6–6.3)
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surprisingly, an even higher representation of trisomy 8 was
observed. Del(5q) was the third most common single abnor-
mality, and it should be marked that seven elderly patients, in
whom Del-5q plus additional evolutionary clones were
detected at baseline, were referred when their clinical situation
had worsened. In these patients there was a period of macro-
cytic anemia, not requiring transfusions for 1–6 years before
their referral, and therefore they might initially be true cases of
Del-5q syndrome, diagnosed during disease progression. Dis-
tribution according to IPSS and WPSS as well as rate of
leukemic transformation were in agreement with reports of
previous studies [17] and were not significantly different in
relation to gender, residence area, or geographical prefecture.
Incidence rates of MDS in Europe have been reported to
vary between 2.1/100,000 inhabitants in the UK during 1984–
1986 [18], 3.2 in France (1980–1990) [9], 3.5 in South
Thames (1999–2000) [10], 3.6 in Sweden (1978–1982) [19],
4.1 (1975–1990) [11] and 4.9 (1996–2005) [13] in Germany
(Düsseldorf), 7.7 in the Basque country (1993–1996) [12], 8.1
in Spain (1994–1998) [14], 9.3 in Somerset, UK [20], and
12.6 in Bournemouth, UK (1981–1990) [6]. A recent study
from Romania found a very low incidence of 0.3/100,000
[21]. In the United States the incidence of MDS has been
reported 3.4/100,000 (SEER, 2001–2003) [22] and
3.3/100,000 (SEER and NAACCR, 2001–2003) [23]. How-
ever, recent studies suggest that many MDS cases are
undetected by cancer registries and constructed algorithms,
and that the true incidence of MDS might be higher [24].
Accordingly, the incidence of MDS in a non-profit healthcare
system in western Washington State rose from 6.9 to 10.2
when possible MDS cases were identified from chart review
[25]. Finally, a study in Japan reported a very low incidence
rate of 1/100,000 inhabitants [26]. The comparison of the
various incidence rates is difficult, because of great differ-
ences in age (excluding pediatric MDS cases leads to higher
incidence rate), in classification (American studies have
adopted ICD classification of MDS), and in time (starting
30 years ago but not referring to the same period, Table 8).
Fig. 2 Comparison between
crude and age-standardized
incidence rate of MDS in rural
and urban areas of SW Greece
(1990–2009)
Fig. 3 Temporal trend of mean
annual incidence rates of MDS
in SW Greece through 1990–
2009 in 5-year periods
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The crude incidence rate of MDS was higher in rural than
in urban areas, but this difference did not persist after age
standardization. In contrast, another study found higher
incidence of MDS in men residing in urban areas [9].
We also observed an increased incidence of MDS in
Achaia, compared to the other prefectures, and this differ-
ence became more prominent after age standardization. Pos-
sible explanations might be the easier access of patients
residing in Achaia to the referral centers, leading to mini-
mization of under-diagnosed cases, and the declaration of
Patras, capital of Achaia, and of the whole region of Western
Greece, residential area of patients’ relatives, as residential
area of patients living in distantly located, particularly rural
areas. This might have led to underestimation of the inci-
dence in the other prefectures of the region, as this has been
observed in the urban areas of Etolia/Akarnania. Other
possible explanations might be the restricted access of dis-
tantly living inhabitants to specialized centers, and the
empirical treatment of less severe cases by family physi-
cians, thus evading correct diagnosis, and the movement of
some patients to referral centers outside Western Greece,
particularly in Athens, where their relatives live and work.
Increasing incidence of MDS has been reported by
McNally et al. [27] and by Aul et al. [11, 28] during the
first period of the Düsseldorf study, but incidence rate
reached a plateau in 1986, without further increase during
the second period (1991–2001) [29]. Neukirchen et al. also
calculated the incidence of MDS in Düsseldorf during the
period 1996–2005 and found no further increase in the
period 2002–2005 [13]. In our study, a continuously in-
creasing incidence of MDS has been observed throughout
the 20-year period, but this entirely concerned the lower-risk
categories. This could be attributed to a better quality of
health care, provided to the elderly population, and conse-
quently to the prolongation of life expectancy. Another most
possible explanation might be the higher degree of suspicion
Table 8 Comparison between incidence rates of MDS from several epidemiologic studies
Authors Country (area) Population
(inhabitants)
Age of study
population
Period Type of MDS
included
Incidence rate
(95 % CI) per
100,000/year
Radlund et al. [19] Sweden (Jönköping) 224,000 >19 years old 1978–1992 FAB classification 3.2 (1978–1982)]
4.1 (1983–1987)]
3.6 mean
3.5 (1988–1992)]
Maynadié et al. [9] France (Côte d’ Or,
Burgundy)
493,931 All ages 1980–1990 FAB classification 3.2 (crude)
1.7 (age adjusted)
Williamson et al. [6] UK (Bournemouth) 214,500 1981–1990 FAB classification 12.6 (crude)
Cartwright RA-
Leukemia
Research Fund
Centre [18]
UK (East Dorset) 11,000,000 1984–1986 2.1 (age adjusted)
Aul C et al. [10] Germany (Düsseldorf) 575,000 1975–1990 FAB classification 1.4–4.1 (crude)
Germing U et al. [29] Germany (Düsseldorf) 575,000 1991–2001 FAB classification 4.9 (crude)
Neukirchen J et al. [13] Germany 575,000 All ages 2002–2005 WHO classification 3.4 (crude)
(Düsseldorf) FAB classification 4.15 (crude)
Shimizu Η et al. [26] Japan (nationwide) 160,000,000 Sept. 1991 1.0 (crude)
Bauduer et al. [12] France (Pays Basque) 290,000 All ages 1993–1996 FAB classification 7.7
Phillips MJ et al. [20] UK (Somerset) 1985–1993 9.3
Iglesias Gallego M
et al. [14]
Spain (Ourense) 346,913 All ages 1994–1998 FAB classification 8.1
Phekoo J et al. [10] UK (South Thames) 5,499,841 ≥16 years old 1999–2000 FAB classification 3.5
Ma X et al. [22] USA (SEER-17 regions) 75,000,000 All ages 2001–2003 ICD-O3 classificationa 3.4 (3.3–3.5)
Rollison DE et al. [23] USA (NAACCR, SEER) 759,270,956 All ages 2001–2004 ICD-O3 classificationa 3.3
Gologan R [21] Romania (Bucharest area) 5,560,566 >16 years old 1985–2004 FAB classification 0.3
Present study Western Greece (Achaia, Ilia,
Etolia and Akarnania)
603,543 ≥15 years old 1990–2009 FAB classification
excluding
CMML/RAEB-T
6.0 (5.6–6.4)
(crude)
5.7 (5.3–6.1)
(age adjusted)
4.8 (4.4–5.2)
a CMML and RAEB-T excluded
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and awareness of the primary medical care providers, prob-
ably also as a result of the broader use of automatic blood
analyzers, and the increasing referral of early-MDS cases,
for evaluation to the specialized Hematological Depart-
ments, cases which were not usually referred in the past.
Alternatively, it could reflect a true increase, related to
environmental factors. Therefore, further epidemiological
research with case–control studies is required, in order to
investigate the possible contribution of environmental, oc-
cupational, and lifestyle factors to the continuous increase of
MDS, particularly of the lower-risk categories, in our area.
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